Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Cantor Fitzgerald issued their FY2026 EPS estimates for Gossamer Bio in a report issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the company will post earnings per share of ($0.45) for the year. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share.
Several other research analysts have also issued reports on GOSS. Wedbush restated an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research report on Friday, May 16th. The Goldman Sachs Group upped their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, May 16th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Tuesday, March 18th.
Get Our Latest Analysis on Gossamer Bio
Gossamer Bio Stock Down 6.0%
Shares of NASDAQ:GOSS traded down $0.08 during midday trading on Tuesday, reaching $1.25. The company had a trading volume of 1,491,453 shares, compared to its average volume of 1,554,200. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The stock's fifty day moving average price is $1.02 and its 200-day moving average price is $1.04. Gossamer Bio has a one year low of $0.50 and a one year high of $1.55. The stock has a market capitalization of $284.13 million, a P/E ratio of -3.91 and a beta of 1.85.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to analyst estimates of $3.95 million.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in GOSS. Graham Capital Management L.P. bought a new position in shares of Gossamer Bio in the 4th quarter valued at $32,000. Virtu Financial LLC acquired a new stake in shares of Gossamer Bio in the first quarter valued at about $38,000. Fullcircle Wealth LLC bought a new position in Gossamer Bio during the 4th quarter worth approximately $43,000. Invesco Ltd. bought a new stake in Gossamer Bio during the first quarter valued at $48,000. Finally, Velan Capital Investment Management LP bought a new stake in Gossamer Bio in the fourth quarter worth approximately $68,000. Institutional investors and hedge funds own 81.23% of the company's stock.
About Gossamer Bio
(
Get Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Read More
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
